FDA Approves Investigational Device Exemption for RadioGel® to Begin Human Clinical Study for Cancer

Vivos Inc. has received U.S. FDA approval for its Investigational Device Exemption (IDE) application, allowing it to initiate a first-in-human feasibility study for RadioGel®. This innovative yttrium-90-based injectable hydrogel is designed for the targeted treatment of cancerous tumors, specifically non-resectable papillary thyroid carcinoma, and will be conducted at Mayo Clinic.

Context

Vivos Inc. has developed RadioGel®, an injectable hydrogel that utilizes yttrium-90 to target cancerous tumors. The treatment is specifically aimed at non-resectable papillary thyroid carcinoma, a condition where surgical removal of the tumor is not possible. The FDA's IDE approval allows the company to begin its first human feasibility study at the Mayo Clinic, a leading medical research institution.

Why it matters

The FDA's approval of the Investigational Device Exemption for RadioGel® marks a significant step in cancer treatment innovation. This new therapy offers a targeted approach to treating specific types of cancer, potentially improving patient outcomes. The ability to conduct human clinical studies is crucial for advancing medical research and developing new treatment options.

Implications

If successful, RadioGel® could offer a new treatment option for patients with non-resectable papillary thyroid carcinoma, potentially improving survival rates and quality of life. The study's outcomes may also impact the broader field of cancer treatment, encouraging further research into similar therapies. Patients, healthcare providers, and investors in the biotech sector may all be significantly affected by the results of this clinical study.

What to watch

The upcoming clinical study will provide critical data on the safety and efficacy of RadioGel® in human subjects. Researchers and healthcare professionals will closely monitor the study's progress and results, which could influence future treatment protocols for thyroid cancer. Additionally, the response from the medical community and potential regulatory developments will be important indicators of the therapy's future.